The metabolomic profile associated with clustering of cardiovascular risk factors-A multi-sample evaluation.

BACKGROUND: A clustering of cardiovascular risk factors is denoted the metabolic syndrome (MetS), but the mechanistic underpinnings of this clustering is not clear. Using large-scale metabolomics, we aimed to find a metabolic profile common for all five components of MetS. METHODS AND
FINDINGS: 791 annotated non-xenobiotic metabolites were measured by ultra-performance liquid chromatography tandem mass spectrometry in five different population-based samples (Discovery samples: EpiHealth, n = 2342 and SCAPIS-Uppsala, n = 4985. Replication sample: SCAPIS-Malmö, n = 3978, Characterization samples: PIVUS, n = 604 and POEM, n = 501). MetS was defined by the NCEP/consensus criteria. Fifteen metabolites were related to all five components of MetS (blood pressure, waist circumference, glucose, HDL-cholesterol and triglycerides) at a false discovery rate of <0.05 with adjustments for BMI and several life-style factors. They represented different metabolic classes, such as amino acids, simple carbohydrates, androgenic steroids, corticosteroids, co-factors and vitamins, ceramides, carnitines, fatty acids, phospholipids and metabolonic lactone sulfate. All 15 metabolites were related to insulin sensitivity (Matsuda index) in POEM, but only Palmitoyl-oleoyl-GPE (16:0/18:1), a glycerophospholipid, was related to incident cardiovascular disease over 8.6 years follow-up in the EpiHealth sample following adjustment for cardiovascular risk factors (HR 1.32 for a SD change, 95%CI 1.07-1.63).
CONCLUSION: A complex metabolic profile was related to all cardiovascular risk factors included in MetS independently of BMI. This profile was also related to insulin sensitivity, which provide further support for the importance of insulin sensitivity as an important underlying mechanism in the clustering of cardiovascular risk factors.

Introduction

In 1988, Reaven and others suggested the existence of a metabolic syndrome (MetS), a clustering of cardiovascular risk factors [1, 2] in certain individuals, with insulin resistance as a common denominator. However, the molecular mechanisms behind the clustering of cardiovascular risk factors seen in some individuals are not clear.

One way to disclose novel mechanisms is to use genomics to search for genetic loci being in common for the components included in the most frequently used definition of the syndrome (NCEP/consensus criteria; high blood pressure, increased waist circumference, high fasting glucose, low HDL-cholesterol and increased triglycerides.). Using this genomic approach, three loci were related to all five MetS components in one study (nearest genes LINC0112, C5orf67, and GIP) [3].

Another way is to use proteomics in a similar fashion. In such attempt using targeted proteomics [4], we found 20 proteins being related to all five MetS components, representing several pathophysiological pathways. (immunomodulation at different level, regulation of adipocyte differentiation, lipid, carbohydrate, and amino acid metabolism; or insulin-like growth factor signaling).

A third -omics technology frequently used nowadays is metabolomics, including small compounds with a molecular weight <1.5 kD. Metabolomics have extensively been used to characterize the metabolic landscape of obesity and diabetes [5, 6]. Moreover, several studies have also been published on metabolomics in MetS [7]. Most of those studies have evaluated individuals with MetS vs controls, while no study has reported the metabolic fingerprint being related to all risk factors in the syndrome. Thus, despite these previous studies there is still a knowledge gap in that respect. We hypothesized that an identification of the metabolic fingerprint being related to all risk factors in the syndrome could shed a light on the underlying mechanisms behind the clustering of cardiovascular risk factors.

It is well known that MetS is related to future atherosclerotic cardiovascular disease (CVD) events [8, 9], although the increased risk by having MetS is not greater than sum of the risk factors included in the syndrome [10]. It would therefore be of interest to investigate if the metabolic fingerprint being related to all risk factors in the syndrome also is related to future atherosclerotic events.

In the present study, the primary aim was to use large-scale metabolomics data to identify metabolites common to all cardiovascular risk factors included in MetS. For this task, we used data from three different cohorts with together >11,000 individuals using a discovery/validation approach. As a secondary aim, we further evaluated if the identified metabolic profile being related to all five MetS components was associated with prevalent MetS in another two cohorts, as well as with insulin resistance. A third aim was to investigate if metabolites being related to all risk factors in the syndrome also was related to future atherosclerotic events.

Material and methods

Study samples

Four different population-based samples were used in the present study. All studies were conducted in accordance with the principles of the Declaration of Helsinki, approved by the responsible ethics committees, and written informed consent was obtained from all participants (Etikprövningsmyndigheten; Dnr 2021–00134).

SCAPIS (Swedish CArdioPulmonary imaging study)

As a collaboration project between six Swedish universities, a total of 30,000 men and women aged 50–65 years have been investigated in six Swedish cities [11].

Besides quantification of traditional cardiovascular risk factors, an extensive imaging program has been performed, including computed tomography (CT) coronary angiography, and carotid artery atherosclerosis with ultrasound. Metabolomic measurements have been performed in 4985 individuals collected in Uppsala and in 3978 individuals collected in Malmö. The data collected at the two sites were treated as separate samples in our statistical analyses.

EpiHealth

Starting April 27th 2011, men and women in the age groups 45 to 75 in two Swedish towns, Uppsala and Malmö, have been invited in a random fashion to a health screening survey, called EpiHealth [12]. In 2018, data on approximately 25,000 individuals had been collected. Traditional CV risk factors and fat mass (bioimpedance) have been recorded. Metabolomic data have been collected in a subsample of subjects attending the Uppsala part of the study (n = 2342). This sample has been followed for almost 10 years regarding incident CVD.

POEM (Prospective investigation of obesity, energy and metabolism)

The population-based POEM study was conducted in men and women living in Uppsala, Sweden all aged 50 years [13]. Between Oct 2010 and Oct 2016, 502 individuals were investigated. A 2h OGTT with insulin determinations each 30th min was performed for calculations of insulin sensitivity. Metabolomics measurements have been performed in all participants, but one (due to missing plasma).

PIVUS (Prospective investigation of the vasculature in Uppsala seniors)

The population-based PIVUS study was conducted in men and women living in Uppsala, Sweden all aged 70 years [14]. Between April 2001 and June 2004, 1016 individuals were investigated. The investigation was repeated at ages 75 and 80 years. At the age of 80, metabolomics measurements were performed in the total sample (n = 604).

In all samples, but EpiHealth, fasting blood samples were collected in the morning after an overnight fast. In EpiHealth, blood samples were collected after 6 hours of fasting. Blood lipids and glucose were measured locally at the hospitals in Uppsala and Malmö, respectively. Blood pressure was measured twice in sitting position and the mean value was used. Waist circumference was measured at the umbilical level. BMI was calculated from height and weight measurements.

The metabolic syndrome (MetS) was determined using the NCEP-based consensus criteria [15]. The five components were defined as follows: Blood pressure ≥ 130/85 mmHg or antihypertensive treatment, fasting plasma glucose ≥ 6.1 mmol/l or antidiabetic treatment, serum triglycerides ≥ 1.7 mmol/l, waist circumference > 102 cm in men and > 88 cm in women, HDL-cholesterol < 1.0 mmol/l in men and < 1.3 in women. Three of the mentioned five criteria should be fulfilled for MetS.

Alcohol intake, smoking habits, exercise habits and education level were assessed by questionnaires.

In the POEM study only, an 2h oral glucose tolerance test (OGTT, 75g glucose) was carried out and glucose and insulin were measured at times 0, 30, 60, 90, and 120 min. From these data, insulin sensitivity was assessed by the Matsuda index [16].

Metabolomics

In all samples, non-targeted metabolomics (Metabolon inc., USA) was performed on plasma samples being stored at -80° C. Samples were prepared using the automated MicroLab STAR® system from Hamilton Company. Several recovery standards were added prior to the first step in the extraction process for quality control purposes. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two separate reverse phases (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. Only annotated, non-xenobiotic metabolites with a call rate >75% in were used in the analyses (n = 791). The values were normalized and given in arbitrary units.

Atherosclerotic CVD definition

Using data from the Swedish cause of death and in-hospital care registers, we defined a combined end-point for atherosclerotic CVD being either fatal or non-fatal acute myocardial infarction or ischemic stroke (ICD-10 codes I20 or I63-I66). Incident cases of atherosclerotic CVD were only investigated in the EpiHealth sample, since the other samples had yet too short follow-up period. The median follow-up period in EpiHealth was 8.6 years. The censor date of the follow-up was Dec 31, 2020.

Statistics

All metabolomic data were subjected to inverse rank normalization within each sample.

One linear regression model for each metabolite was performed vs the five MetS components separately (systolic blood pressure (SBP), fasting glucose (GLU), triglycerides (TG), HDL-cholesterol (HDL) and waist circumference (WC)). All of these analyses were adjusted for age, sex and BMI, as well as for the life-style factors alcohol intake, smoking habits, exercise habits and education level. These analyses were carried out separately in SCAPIS-Uppsala, SCAPIS-Malmö and EpiHealth.

We thereafter undertook a discovery/validation approach with an inverse-variant weighted fixed effect meta-analysis of the two Uppsala samples (SCAPIS-Uppsala and EpiHealth) as the discovery step and SCAPIS-Malmö as the validation step. In both steps, we required the metabolites to show a false discovery rate (FDR) <0.05 in order to be judged as a validated metabolite.

The 15 validated metabolites being related to all 5 MetS criteria and with the same sign of the beta coefficient for all risk factors (except for HDL), were one by one related to incident atherosclerotic CVD in the EpiHealth sample using Cox proportional hazard analysis. Two set of adjustments were performed. First, adjustment for age and sex. Second, adjustment also for the classical risk factors systolic blood pressure, smoking (current yes/no), HDL and LDL-cholesterol, BMI and diabetes. FDR<0.05 for the age and sex-adjusted analysis in combination with p<0.05 for the multiple adjustment was regarded as significant in this analysis. Subjects with prevalent CVD at baseline were excluded from this analysis.

The 15 validated metabolites being related to all 5 MetS criteria and with the same sign of the beta coefficient for all risk factors (except for HDL), were one by one related to prevalent MetS in POEM and PIVUS by use of logistic regression analysis adjusting for age, sex and BMI, as well as for the life-style factors smoking habits, exercise habits and education level (no information on alcohol intake). The results from these two studies were then meta-analyzed (inverse-variant weighted fixed effect) and FDR<0.05 was considered as significant.

The 15 validated metabolites being related to all 5 MetS criteria were further investigated for association with insulin resistance (Matsuda index, ln-transformed) in POEM. Linear regression analysis adjusting for age, sex and BMI, as well as for the life-style factors smoking habits, exercise habits and education level (no information on alcohol intake) was carried out for each metabolite. FDR<0.05 was considered as significant.

For the 15 validated metabolites being related to all five MetS components, we searched for genetic associations at http://metabolomics.helmholtz-muenchen.de/gwas/ using the Shin et al. analysis [17] and in the GWAS catalogue: https://www.ebi.ac.uk/gwas/.

We used the Mendelian randomization framework to evaluate shared genetics for these metabolites and genetics for MetS using an already published GWAS for MetS [18]. The Wald ratio was used to obtain the causal estimate when only one locus linked to a metabolite (mQTL) was used as instrumental variable. An inverse-variance weighted fixed-effect meta-analysis (IVW) was used when more than one SNP was used as instrumental variable. Only SNPs with p<5*10−8 and not in LD (<0.001) were used in this evaluation. The genetics for metabolites were downloaded from the KORA Helmholtz Zentrum Munich metabolomics GWAS server (http://metabolomics.helmholtz-muenchen.de/gwas/) [13].

STATA16 (Stat inc, College Station, TX) was used for calculations.

Results

Baseline characteristics of the four cohorts are provided in Table 1.

Table 1

Basic characteristics of the samples.

Means and (SD) are given, or proportions in %.

	SCAPIS-Uppsala	SCAPIS-Malmö	EpiHealth	POEM	PIVUS
n	4985	3978	2342	502	604
Age	57.6 (4.4)	57.4 (4.2)	61.1 (8.4)	50 (0.1)	80 (0.2)
Female sex	51%	52%	50%	50%	50%
Systolic blood pressure (mmHg)	125 (16)	122 (16)	135 (17)	126 (16)	147 (19)
Diastolic blood pressure (mmHg)	77 (10)	75 (10)	83 (9)	77 (10)	74 (9)
HDL-cholesterol (mmol/l)	1.4 (.4)	1.6 (.5)	1.5 (.3)	1.3 (.3)	1.4 (0.4)
Triglycerides (mmol/l)	1.3 (.7)	1.3 (.8)	1.2 (.7)	1.2 (.9)	1.2 (0.6)
BMI (kg/m 2 )	27.0 (4.3)	27.2 (4.5)	26.5 (3.8)	26.4 (4.2)	26.9 (4.6)
Waist circumference (cm)	94.9 (12.8)	95.2 (13.0)	92.5 (11.7)	92.5 (11.4)	96.3 (11.7)
Fasting glucose (mmol/l)	5.7 (1.0)	5.5 (1.2)	5.9 (.9)	4.9 (.9)	5.2 (1.4)
Diabetes medication	4.1%	5.3%	4.4%	0.2%	12%
Antihypertensive medication	19%	21%	22%	8.1%	60%
Alcohol intake	6.9 (6.1) (g/week)	6.9 (6.8) (g/week)	2.43 (2.92) (drinks/week)	NA	NA
Exercise habits	1.69 (1.38) (On a 6 grade scale)	1.58 (1.43) (On a 6 grade scale)	2.29 (.8) (On a 5 grade scale)	2.8 (1.01) (On a 4 grade scale)	1.21 (1.31) (On a 4 grade scale)
Education
<10 years	8%	11%	21%	8%	56%
10–12 years	41%	48%	29%	44%	19%
>12 years	51%	41%	50%	48%	25%
Smokers	9.2%	16%	6.7 years of smoking	9.8%	3.2%

NA = Not assessed

Of the 791 metabolites, 135 metabolites were identified and validated to be associated with SBP, 488 with HDL, 512 with triglycerides, 404 with glucose and 252 were identified to be associated with waist circumference. All analyses were adjusted for age, sex, exercise habits, alcohol intake, education level, smoking and BMI. See overview of the metabolite/MetS components associations in S1 Table.

Fifteen metabolites were associated with all five MetS components (see Fig 1 for overview and S2 Table for details). They represented different metabolic classes, such as amino acids (glycine, S-methylcysteine sulfoxide), simple carbohydrates (glucose, glycerate, lactate), androgenic steroids (11beta-hydroxyandrosterone glucuronide), corticosteroids (cortolone glucuronide, tetrahydrocortisol glucuronide), co-factors and vitamins (oxalate (ethanedioate), carotene diol), ceramides (N-stearoyl-sphinganine (d18:0/18:0)), carnitines (pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)), fatty acids (hydroxy-CMPF), phospholipids (1-palmitoyl-2-oleoyl-phosphatidylethanolamine (GPE) (16:0/18:1)), and metabolonic lactone sulfate.

Fig 1

Circular dendrogram of the 15 validated metabolites (and their chemical class) being related to all five metabolic syndrome (MetS) components.

A dark blue dot corresponds to a positive relationship vs MetS, while a light blue dot represents an inverse association. The details on the strengths of the relationships vs the MetS components are given in S2 Table, while the strengths of the relationships vs MetS (binary) are given in Table 2.

Table 2

Relationships between the 15 validated metabolites being related to all five components in the metabolic syndrome (MetS) and prevalent MetS in a meta-analysis of the PIVUS and POEM samples.

The results are sorted on p-value. A star following the p-value denotes that the metabolite shows a false discovery rate (FDR)<0.05.

Super pathway	Sub pathway	Chemical name	Beta	95%CI lower	95%CI higher	p-value
Lipid	Phosphatidylethanolamine (PE)	1-palmitoyl-2-oleoyl-GPE (16:0/18:1)	.57	.38	.78	1.12e-08*
Cofactors and Vitamins	Vitamin A Metabolism	carotene diol (2)	-.61	-.83	-.4	2.99e-08*
Partially Characterized Molecules	Partially Characterized Molecules	metabolonic lactone sulfate	.58	.38	.8	4.15e-08*
Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism	glucose	.55	.35	.76	8.39e-08*
Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism	lactate	.52	.32	.73	3.52e-07*
Lipid	Dihydroceramides	N-stearoyl-sphinganine (d18:0/18:0)	.43	.23	.64	.000036*
Amino Acid	Glycine, Serine and Threonine Metabolism	glycine	-.33	-.53	-.14	.00070*
Lipid	Corticosteroids	tetrahydrocortisol glucuronide	.29	.09	.49	.0037*
Lipid	Androgenic Steroids	11-beta-hydroxyandrosterone glucuronide	.23	.04	.42	.018*
Lipid	Corticosteroids	cortolone glucuronide	.19	-.01	.41	.058
Lipid	Fatty Acid, Dicarboxylate	hydroxy-CMPF	-.17	-.36	.01	.070
Cofactors and Vitamins	Ascorbate and Aldarate Metabolism	oxalate (ethanedioate)	-.12	-.33	.08	.22
Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism	glycerate	-.099	-.30	.10	.32
Lipid	Fatty Acid Metabolism (Acyl Carnitine, Dicarboxylate)	pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)	-.067	-.25	.12	.46
Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism	S-methylcysteine sulfoxide	-.026	-.22	.16	.77

Nine of those metabolites showed FDR<0.05 vs prevalent MetS in POEM and PIVUS (Table 2).

All 15 metabolites were associated with (FDR<0.05) the Matsuda index in POEM.

In the Epihealth cohort, 98 subjects experienced an atherosclerotic CVD event (myocardial infarction or ischemic stroke) during a median follow-up period of 8.6 years (maximal 9.6 years, 18,922 person years at risk). Two of the 15 metabolites being associated with all five MetS components showed FDR<0.05 in the age and sex-adjusted analysis, but only one metabolite, 1-palmitoyl-2-oleoyl-GPE (16:0/18:1), also showed p<0.05 following adjustment for traditional CVD risk factors (HR 1.32 for a 1 SD change, 95%CI 1.07–1.63, details in Table 3).

Table 3

Relationships between the 15 validated metabolites being related to all five components in the metabolic syndrome (MetS) and incident atherosclerotic cardiovascular disease in the EpiHealth cohort.

	Age and sex-adjusted				Multiple adjusted
Metabolite	HR	95%CI low	95%CI high	p-value	HR	95%CI low	95%CI high	p-value
1-palmitoyl-2-oleoyl-GPE (16:0/18:1)	1.43	1.17	1.75	.00054	1.32	1.07	1.63	.010
N-stearoyl-sphinganine (d18:0/18:0)	1.36	1.11	1.68	.0032	1.23	.98	1.57	.074
S-methylcysteine sulfoxide	.84	.68	1.02	.082	.88	.72	1.08	.23
carotene diol (2)	.84	.69	1.04	.10	.92	.73	1.15	.45
hydroxy-CMPF	.87	.71	1.06	.17	.96	.78	1.2	.74
tetrahydrocortisol glucuronide	1.14	.92	1.4	.23	1	.8	1.25	.99
oxalate (ethanedioate)	.89	.71	1.09	.24	.98	.79	1.22	.84
glycine	.89	.72	1.11	.28	.96	.76	1.21	.72
lactate	1.12	.91	1.36	.28	1	.81	1.25	.97
glycerate	.9	.74	1.12	.34	.99	.79	1.22	.89
metabolonic lactone sulfate	1.09	.89	1.34	.39	.94	.75	1.19	.62
pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)	.94	.77	1.15	.55	1.02	.83	1.27	.82
cortolone glucuronide (1)	1.01	.83	1.25	.92	.85	.68	1.06	.15
11beta-hydroxyandrosterone glucuronide	1.01	.83	1.23	.92	.94	.76	1.16	.59
glucose	1	.82	1.22	.98	.86	.68	1.07	.18

Of the 15 validated metabolites, we could only find published associated genetic variants (mQTL) with p<5*10−8 for glycine (rs715, position chr2:211543055:T/C, nearest gene CPS1). The Wald ratio for this loci vs MetS genetics was not significant (beta 0.11, SE 0.09, p-value 0.20). We did not evaluate if the metabolite glucose is causally related to MetS, since the glucose criteria is a part of MetS.

In the GWAS for MetS, 91 independent loci with p<5*10−8 were found [14]. When these loci were used as genetic instruments vs genetic data for glycine, glycerate or lactate (the only metabolites for which GWAS data were found), evidence was found for an association between shared genes between MetS and glycine (IVW beta 0.021, SE 0.007, p = 0.0027), but not for glycerate (IVW beta -0.0025, SE 0.006, p = 0.71), while lactate was of borderline significance (IVW beta 0.012, SE 0.006, p = 0.052).

Discussion

The present study using several large samples identified 15 metabolites from a wide variety of metabolic pathways to be significantly related to all five components of the MetS. All of them were related to insulin sensitivity. One of these metabolites were related to incident CVD, 1-palmitoyl-2-oleoyl-GPE (16:0/18:1).

Previous studies have identified carnitine, 2-deoxyglucose, phenylalanine [19] hippurate [20], phosphatidylcholine 34:2, trimethylamine N-oxide (TMAO) [21, 22] glucose, aromatic amino acids, salicyluric acid, maltitol, and p-cresol sulfate [23] to be linked to MetS. Using two independent samples, Roberts et al found 18 replicated metabolites to be linked to MetS, with representation from branched-chain amino acid metabolism, glutathione production, aromatic amino acid metabolism, gluconeogenesis, and the tricarboxylic acid cycle [24]. In another study [25], 16 metabolites, including carbohydrates, amino acids and several cholines was able to discriminate the MetS subjects vs controls with a C-statistic of 0.96. The novelty with the present study is that we identified metabolites related to all five components of the syndrome independent of BMI, with the hypothesis that some of these metabolites could be involved in pathways leading to the clustering of risk factors seen in some individuals.

All analyses in the present study were adjusted for BMI. This was done because obesity as such is related to each of the five MetS components, and we do not want to produce a long list of metabolites being related to all of the five MetS components just due to the fact that they are related to obesity. The fact that some metabolites are associated with both obesity (BMI) as such and fat distribution (WC) might be the reason why some obesity-related metabolites were related to all 5 risk factors despite adjustment for BMI.

Of interest is to note that the 15 metabolites found to be related to all five MetS components are involved in a variety of different metabolic classes, including amino acids, simple carbohydrates, androgenic steroids and corticosteroids, ceramides, carnitines, and phospholipids. However, which of these metabolic classes that are involved in the pathogenesis of the clustering of risk factors could not be told from the present study.

MetS has been linked to the major cardiovascular diseases, myocardial infarction, stroke and heart failure [8]. MetS has also been linked to other adverse cardiovascular conditions, such as a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation [26] and a proarrythmogennic state in heart failure patients treated with an internal cardioverter defibrillator (ICD) [27]. An increased level of inflammation [28] together with over-stretch of cardiac muscle and fibrosis development due to MetS could lead to cardiac electrophysiological alterations, a poor myocardial performance and clinical outcome in the patients affected by MetS [29].

We found one metabolite, 1-palmitoyl-2-oleoyl-GPE (16:0/18:1), being related to all 5 MetS components in a validated fashion, to be associated with incidentCVD. Phosphatidyl-ethanolamines (GPE) are glycerophospholipids being mainly found on the inner part of the cell membrane and have been suggested to be involved in multiple actions, such as protein breakdown, mitochondrial function, autophagy and membrane fusion. One small case-control study of patients with lucunar brain infarcts showed GPE (35:2) to be increased in the cases [30]. Phosphatidylethanolamine (20:0/18:2) has been found to be reduced in subjects with severe coronary atherosclerosis [31]. It should however be acknowledged that the function of PEs might well be affected by the fatty acids included in the GPE. The fatty acids 16:0 and 18:1 included in 1-palmitoyl-2-oleoyl-GPE have both been associated with unwarranted health outcomes, such as insulin resistance, diabetes and myocardial infarction [32-34].

Already in the description of MetS in 1988 [1], insulin resistance was suggested to be the major mechanism behind the clustering of risk factors. It is therefore of interest to note that all of the 15 validated metabolites also were associated with insulin resistance as measured by the Matsuda index in a separate cohort following adjustment for BMI.

In light of the present findings that the metabolomic profile being in common for the five MetS components is very similar to that seen in insulin resistance, it would be of interest to evaluate the metabolomic profile in lean subjects with insulin resistance, as this group often suffer from NAFLD and have an increased risk of CVD [35, 36]. However, in the only study in which we have data on liver fat (the POEM study), only 3 subjects were classified as being lean and insulin resistant, so meaningful statistical evaluation of the metabolomic profile in this interesting group cannot be performed.

The major strength of the present study is the use of several independent large studies that made it possible to perform a discovery/validation approach with a good power despite the large number of metabolites evaluated. Another strength is that we had another two samples to test if the 15 metabolites also were linked to prevalent MetS and insulin resistance. The major weakness is that we ideally wanted to test the 15 metabolites vs incident MetS, but did not have a follow-up of future MetS in any of the samples. We did however have follow-up of incident cases of CVD, but since the number of cases were rather low, we did have a limited power to detect significant association, especially following multiple adjustment. This will possibly lead to false negative associations between some metabolites and incident CVD. We also acknowledge that we have been studying almost exclusively Swedish subjects with European descent and that our results have to be reproduced in other countries and in other ethnic groups. Another limitation is that we do not have access to strong genetic instruments for most metabolites, so the issue on causality could not be properly addressed by genetic studies. No formal power calculation was performed. The study is however the largest study (>11,000 individuals) performed regarding a large set of metabolites (n = 791) and MetS, so the power to find significant associations was substantially higher than in the previous literature.

In conclusion, a complex metabolic profile was disclosed being related to a clustering of the cardiovascular risk factors included in MetS. This profile was also related to the Matsuda index, further emphasizing the importance of insulin sensitivity as an important underlying mechanism behind the clustering of risk factors. One of the metabolites been related to all MetS components, 1-palmitoyl-2-oleoyl-GPE (16:0/18:1), was also related to incident CVD, suggesting that this metabolite is worthwhile to explore in more detail as a potential mediator in the MetS vs atherosclerotic CVD relationship.

Overview of the metabolites being associated with at least one of the five MetS criteria.

The criteria are given together with sum of criteria. The table was sorted on sum of criteria.

(DOCX)

Click here for additional data file.

Relationships between the 15 validated metabolites being related to all five components in the metabolic syndrome (MetS) and fasting glucose (GLU), HDL-cholesterol, systolic blood pressure (SBP), triglycerides (TG) and waist circumference (WC).

The estimates are from the validation step in the SCAPIS-Malmö cohort. No relationship for the metabolite glucose vs the GLU criteria is shown.

(DOCX)

Click here for additional data file.

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

25 Jul 2022

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ferdinando Carlo Sasso, PhD, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. Please also state whether your data was analysed anonymously or if you had access to identifying information.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

Additional Editor Comments:

The manuscript is interesting, but some issues need to be addressed by authors. Please, submit a revised version of your manuscript possibly within 2 weeks.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I read with great interest the paper “The metabolomic profile associated with clustering of cardiovascular risk factors – a multi-sample evaluation" by Lind et al.

The article is well written. Paper design must be improved. The article is logically divided into sections and subsections.

Comments:

1. Line 64-65: please better specify the criteria for metabolic syndrome diagnosis. High blood pressure or in treatment, low HDL, high triglycerides levels…

2. Line 79-81: I suggest the author to modify accordingly: “Metabolomics have extensively been used to characterize the metabolic landscape of obesity and diabetes [6, 7]. Moreover, several studies have also been published on metabolomics in MetS [8]”.

3. The key role of insulin resistance in metabolic syndrome have been stressed in various research, and it has been mostly associated with visceral adipose. However, newer reports have reported the presence of insulin resistance in lean individuals, with NAFLD development, as well as increased cardiovascular disease development (doi: 10.3390/antiox10020270; doi: 10.37349/emed.2020.00019). Pathophysiological mechanisms are still not clear. Though, the suggested metabolomics could be implicated in this process. Is there any evidence in such individuals? Do you have any data?

Reviewer #2: INTRODUCTION:

It is too long and not well focused on main study background, hypothesis, literature gap, and aim.

Please introduce the full diagnostic criteria for Metabolic Syndrome (MS), the criteria that you will use for all study. Add it in detail in the Methods.

Please add more information about MS and cardiovascular diseases (CVDs) genesis and prognosis. Indeed, authors showed that MS could favor an arrhythmic status leading to enhanced automatism and higher rate of arrhythmic events with consequent refractoriness to ablative approaches and worse clinical outcomes (Cardiovasc Disord. 2014 Dec 6;14:176. doi: 10.1186/1471-2261-14-176). Please discuss this point.

Again, the MS could cause over-inflammation and over-stretch of cardiac muscle (Front Physiol. 2018 Jun 26;9:758. doi: 10.3389/fphys.2018.00758), leading to worse prognosis by higher rate of arrhythmic atrial and ventricular events, ICDs’ therapies and hospitalizations. In this case, the MS could result in the compromising of functional status of heart failure patients treated with ICDs (Front Physiol. 2018 Jun 26;9:758. doi: 10.3389/fphys.2018.00758). Indeed, the MS could lead to cardiac electrophysiological alterations and clinical response in the treated patients affected by MS, by anormalities of sensing, (pacing) and impedance parameters (Medicine (Baltimore). 2017 Apr;96(14):e6558. doi: 10.1097/MD.0000000000006558). Please discuss this point and the adverse association between MS and HF.

METHODS:

Do you have number of ethical committee? Please add it.

How did you calculate the study sample size?

Please include a full description of incident atherosclerotic cardiovascular disease.

RESULTS:

I see a low percentage (0.2-12%) of diabetes medications. Please explain this point.

DISCUSSION:

Please focus the Discussion of 3 pages of description, and include according to authors (Curr Pharm Des. 2020;26(22):2565-2573. doi: 10.2174/1381612826666200213123029. ), the importance of over-inflammation in the pathogenesis and worse prognosis of CVDs, as in the case (see comments before) of MS. Please discuss it.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

29 Aug 2022

Reviewer #1: I read with great interest the paper “The metabolomic profile associated with clustering of cardiovascular risk factors – a multi-sample evaluation" by Lind et al.

The article is well written. Paper design must be improved. The article is logically divided into sections and subsections.

Comments:

1. Line 64-65: please better specify the criteria for metabolic syndrome diagnosis. High blood pressure or in treatment, low HDL, high triglycerides levels…

Reply: We have now better specified the criteria for metabolic syndrome diagnosis: “high blood pressure, increased waist circumference, high fasting glucose, low HDL-cholesterol and increased triglycerides.” (line 63-64)

In addition, we have given the details used to define the 5 components in the methods section: high blood pressure, increased waist circumference, high fasting glucose, low HDL-cholesterol and increased triglycerides (line 139-143) “The five components were defined as follows: Blood pressure ≥ 130/85 mmHg or antihypertensive treatment, fasting plasma glucose ≥ 6.1 mmol/l or antidiabetic treatment, serum triglycerides ≥ 1.7 mmol/l, waist circumference > 102 cm in men and > 88 cm in women, HDL-cholesterol < 1.0 mmol/l in men and < 1.3 in women. Three of the mentioned five criteria should be fulfilled for MetS.”

2. Line 79-81: I suggest the author to modify accordingly: “Metabolomics have extensively been used to characterize the metabolic landscape of obesity and diabetes [6, 7]. Moreover, several studies have also been published on metabolomics in MetS [8]”.

Reply: This part has now been changed according to your suggestion (line 74-76).

3. The key role of insulin resistance in metabolic syndrome have been stressed in various research, and it has been mostly associated with visceral adipose. However, newer reports have reported the presence of insulin resistance in lean individuals, with NAFLD development, as well as increased cardiovascular disease development (doi: 10.3390/antiox10020270; doi: 10.37349/emed.2020.00019). Pathophysiological mechanisms are still not clear. Though, the suggested metabolomics could be implicated in this process. Is there any evidence in such individuals? Do you have any data?

Reply: This is a good idea! This lean insulin resistant group with NAFLD is very interesting. However, in the only study in which we have data on liver fat (the POEM study), only 3 subjects were classified as being lean and insulin resistant, so meaningful statistical evaluation of the metabolomic profile in this interesting group cannot be performed. We have now added a para on this idea in the discussion section, including the references you suggested (line 339-345): “In light of the present findings that the metabolomic profile being in common for the five MetS components is very similar to that seen in insulin resistance, it would be of interest to evaluate the metabolomic profile in lean subjects with insulin resistance, as this group often suffer from NAFLD and have an increased risk of CVD [35,36]. However, in the only study in which we have data on liver fat (the POEM study), only 3 subjects were classified as being lean and insulin resistant, so meaningful statistical evaluation of the metabolomic profile in this interesting group cannot be performed.”

Reviewer #2: INTRODUCTION:

It is too long and not well focused on main study background, hypothesis, literature gap, and aim.

Reply: We have now shortened the introduction and tried to be more focused on the items you suggest.

Please introduce the full diagnostic criteria for Metabolic Syndrome (MS), the criteria that you will use for all study. Add it in detail in the Methods.

Reply: We have now given the details used to define the 5 components in the methods section: high blood pressure, increased waist circumference, high fasting glucose, low HDL-cholesterol and increased triglycerides (line 139-143) “The five components were defined as follows: Blood pressure ≥ 130/85 mmHg or antihypertensive treatment, fasting plasma glucose ≥ 6.1 mmol/l or antidiabetic treatment, serum triglycerides ≥ 1.7 mmol/l, waist circumference > 102 cm in men and > 88 cm in women, HDL-cholesterol < 1.0 mmol/l in men and < 1.3 in women. Three of the mentioned five criteria should be fulfilled for MetS.”

Please add more information about MS and cardiovascular diseases (CVDs) genesis and prognosis. Indeed, authors showed that MS could favor an arrhythmic status leading to enhanced automatism and higher rate of arrhythmic events with consequent refractoriness to ablative approaches and worse clinical outcomes (Cardiovasc Disord. 2014 Dec 6;14:176. doi: 10.1186/1471-2261-14-176). Please discuss this point.

Again, the MS could cause over-inflammation and over-stretch of cardiac muscle (Front Physiol. 2018 Jun 26;9:758. doi: 10.3389/fphys.2018.00758), leading to worse prognosis by higher rate of arrhythmic atrial and ventricular events, ICDs’ therapies and hospitalizations. In this case, the MS could result in the compromising of functional status of heart failure patients treated with ICDs (Front Physiol. 2018 Jun 26;9:758. doi: 10.3389/fphys.2018.00758). Indeed, the MS could lead to cardiac electrophysiological alterations and clinical response in the treated patients affected by MS, by anormalities of sensing, (pacing) and impedance parameters (Medicine (Baltimore). 2017 Apr;96(14):e6558. doi: 10.1097/MD.0000000000006558). Please discuss this point and the adverse association between MS and HF.

Reply: We have included a new paragraph in the discussion section discussing the issues of hyperinflammation, ICD, cardiac stretch and heart failure in relation to MetS with three new references mentioned by you. However, since you wanted to reduce the discussion part to three pages, this added paragraph had to be kept short (line 315-322):” MetS has been linked to the major cardiovascular diseases, myocardial infarction, stroke and heart failure [9]. MetS has also been linked to other adverse cardiovascular conditions, such as a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation [26] and a proarrythmogennic state in heart failure patients treated with an internal cardioverter defibrillator (ICD) [27]. An increased level of inflammation [28] together with over-stretch of cardiac muscle and fibrosis development due to MetS could lead to cardiac electrophysiological alterations, a poor myocardial performance and clinical outcome in the patients affected by MetS [29].”

METHODS:

Do you have number of ethical committee? Please add it.

Reply: This has now been added (line 102): “Dnr 2021-00134”

How did you calculate the study sample size?

Reply: No formal power calculation was performed. The study is however the largest study (>11,000 individuals) performed regarding a large set of metabolites (n=791) and MetS, so the power to find significant association is higher than in the previous literature. We have now added to the discussion (line 359-362):” No formal power calculation was performed. The study is however the largest study (>11000 individuals) performed regarding a large set of metabolites (n=791) and MetS, so the power to find significant associations was substantially higher than in the previous literature.”

Please include a full description of incident atherosclerotic cardiovascular disease.

Reply: We have now added more information regarding the evaluation of incident atherosclerotic cardiovascular disease. If you like us to add some additional information, please let us know.” Using data from the Swedish cause of death and in-hospital care registers, we defined a combined end-point for atherosclerotic CVD being either fatal or non-fatal acute myocardial infarction or ischemic stroke (ICD-10 codes I20 or I63-I66). Incident cases of atherosclerotic CVD were only investigated in the EpiHealth sample, since the other samples had yet too short follow-up period. The median follow-up period in EpiHealth was 8.6 years. The censor date of the follow-up was Dec 31, 2020.” (line 166-171)

RESULTS:

I see a low percentage (0.2-12%) of diabetes medications. Please explain this point.

Reply: This wide range in diabetes prevalence is due to the fact that the range in age is large between the samples. The diabetes prevalence in the different age-groups are similar to other Swedish cohort studies, so from our perspective the percentage (0.2-12%) of diabetes medications is not surprising.

DISCUSSION:

Please focus the Discussion of 3 pages of description, and include according to authors (Curr Pharm Des. 2020;26(22):2565-2573. doi: 10.2174/1381612826666200213123029. ), the importance of over-inflammation in the pathogenesis and worse prognosis of CVDs, as in the case (see comments before) of MS. Please discuss it.

Reply: We have now condensed the discussion to three pages. We have now discussed the proinflammatory state as a driver of CVD in subjects with MetS, as commented before.

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

2 Sep 2022

The metabolomic profile associated with clustering of cardiovascular risk factors – a multi-sample evaluation

PONE-D-22-17734R1

Dear Dr. Lind,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ferdinando Carlo Sasso, PhD, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors addressed all issues raised by reviewers. No further comments.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The paper has much improved and the authors managed to respond to all the issues I raised. The paper can be further processed for publication.

Reviewer #2: The authors revised the article according to reviewers' comments.

In my opinion, you could be accepted for a possible pubblication in the journal.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

6 Sep 2022

PONE-D-22-17734R1

The metabolomic profile associated with clustering of cardiovascular risk factors – a multi-sample evaluation

Dear Dr. Lind:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Ferdinando Carlo Sasso

Academic Editor

PLOS ONE